分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Pleckstrin 2 is a potential drug target for colorectal carcinoma with activation of APC/β‑catenin

Bao Chai, Yarong Guo, Na Zhu, Junmei Jia, Zhuowei Zhang, Mei Ping, Kai Jia, Xiaolong Cui, Yuhong Suo

Journal:Molecular Medicine Reports

IF:2.95

DOI:10.3892/mmr.2021.12502

PMID:34676872

Published:2021-10-19

research field:肿瘤学分子生物学细胞生物学

Abstract

The tumor suppressor gene adenomatous polyposis coli (APC) is frequently inactivated or absent in colorectal carcinoma (CRC). Loss‑of‑function of APC promotes the expression of β‑catenin, which is critical for CRC development. Since β‑catenin acts as an important transcription factor, blockage of β‑catenin may have side effects, including impairment of tissue homeostasis and regeneration, thus limiting the application of β‑catenin inhibitors for the treatment of patients with CRC. Therefore, identifying a novel substrate of APC/β‑catenin may provide essential clues to develop effective drugs. Small interfering RNA technology and lentivirus‑mediated overexpression were performed for knockdown and overexpression of pleckstrin 2 (PLEK2) in CRC cells. Cell Counting Kit‑8 and colony formation assays, and cell cycle analysis and cell apoptosis detection were used to detect the capacity of cell proliferation, cell cycle distribution and apoptosis. The present study demonstrated that the APC/β‑catenin signaling cascade transcriptionally activated PLEK2 in CRC cells. PLEK2 expression was markedly increased in CRC tissues. There was an inverse correlation between APC and PLEK2 expression in patients with CRC. <em>In vitro</em>, overexpression of PLEK2 increased the proliferation of CRC cells. Opposite results were observed in the cells with knockdown of PLEK2. Furthermore, PLEK2 promoted cell cycle progression and suppressed apoptosis. In summary, upregulation of PLEK2 contributed to CRC proliferation and colony formation activated by the APC/β‑catenin signal pathway. Targeting PLEK2 may be important for the treatment of patients with CRC with activation of the APC/β‑catenin signaling pathway.

本文使用的Yeasen产品

购物车
客服
转染试用